Bayer’s Rally Gets a €3 Billion Anchor: Apollo Deal Follows Supreme Court Victory as the Roundup Saga Rolls On
Published on 07/11/2026 at 07:34 | Redaktion boerse-global.de
Bayer’s stock has more than doubled over the past year, transforming from a litigation-laden laggard into one of the most volatile names in the DAX. But the real story lies in the two distinct forces now shaping the company’s trajectory: a landmark legal win that ignited the rally and a €3 billion cash infusion from Apollo Global Management that gives the balance sheet a much-needed safety net.
The shares closed at €50.18 on Friday, trimming 1% on the day and shedding 5.4% over the week. That short-term pullback barely registers against the broader picture. Over the past 30 days, the stock has surged 42.6%. Year-to-date gains stand at 32%, while the 12-month advance has reached an eye-popping 81%. The 52-week high of €53.86, set on 3 July 2026, now sits just 6.8% above the current price.
The catalyst for that blistering run was a US Supreme Court ruling in late June that Bayer cannot be sued under state-law failure-to-warn claims related to its Roundup herbicide. The decision removed a legal sword of Damocles that had hung over the company for years, sending shares screaming higher. Yet the underlying business remains overshadowed by a tangled web of litigation that is far from settled.
Separately, Bayer announced a deal with Apollo to offload a minority stake in its long-acting reversible contraception (LARC) business — home to hormonal IUDs Mirena, Kyleena and Jaydess — for €3 billion. The unit generated nearly €1.4 billion in revenue last year. Apollo will take a non-controlling interest in a newly formed entity, while Bayer retains operational control and a majority stake. The transaction is expected to close in the third quarter of 2026.
Should investors sell immediately? Or is it worth buying Bayer?
The capital injection is squarely aimed at debt reduction. In February, Bayer agreed to a sweeping Roundup settlement worth up to $7.25 billion. The preliminary approval is in place, and the final fairness hearing is scheduled for 19 August. While management has repeatedly ruled out an equity raise, the Apollo deal allows Bayer to strengthen its balance sheet without diluting existing shareholders.
What makes the stock’s behavior so striking is its near-binary response to legal developments. The 30-day annualized volatility has hovered around 62% — a level more typical of micro-cap speculations than a €49.8 billion DAX incumbent. The Relative Strength Index sits at 70.4, deep in overbought territory, and the share price trades 33% above its 200-day moving average. Such stretched readings rarely persist for long; they reflect a market that has repriced the company in weeks what normally takes months.
That pricing, however, may overstate the resolution of Bayer’s legal woes. The Supreme Court ruling addressed only a subset of claims. Approximately 4,000 federal cases remain pending (Bayer puts the number closer to 200, citing outdated filings), while over 60,000 similar lawsuits are winding through state courts — an arena the Supreme Court decision is not expected to affect. Bayer continues to pursue the $7.25 billion settlement as a path to broader closure.
Bayer at a turning point? This analysis reveals what investors need to know now.
For now, investors are placing their bets on two tracks: a judicial victory that removed the most existential threat, and a financial restructuring that buys time and flexibility. The Apollo deal adds a tangible balance-sheet buffer, but the final court date on 19 August will test whether the rally has been a genuine re-rating or merely a speculative reprieve.
Ad
Bayer Stock: New Analysis - 11 July
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
